| || ||Dr. Ann Clare Kessler |
Dr. Ann Clare Kessler currently serves on the Board of Directors of MedGenesis Therapeutix, Inc. as well as on the Science Advisory Board of Gen-Probe Inc. For more than thirty years, Dr. Kessler held several senior positions at Hoffmann-La Roche Inc. in the US, including Vice President and Head of Exploratory Research and VP of Pharmacology and Chemotherapy, prior to moving to Switzerland where she was in charge of the International Project Management group of Hoffmann-La Roche in Basel for another 5 years until 1995. Her managerial responsibilities in Research and Development concerned the discovery and development of novel drugs for global registration and launch in a number of therapeutic areas, including nervous system disorders. She has authored over 100 publications dealing with obesity, lipid metabolism and appetite regulation, and has 20 patents issued concerning pharmacological approaches to diseases. Dr. Ann Kessler obtained her B.S. degree from the College of Notre Dame of Maryland in 1965, M.S. in Biological Sciences from Northwestern University, in 1967, and a Ph.D. in Biochemistry from New York University in 1973.
| || ||Armin Kessler |
Armin Kessler has over 35 years experience in the global pharmaceutical industry. His most recent appointment was Chief Operating Officer of Hoffmann-La Roche in Basel, Switzerland. Earlier key positions included Director of Pharmaceutical Marketing and Country Management Worldwide for Sandoz, President of Sandoz KK in Japan and CEO of Roche U.K. In addition he served as President of the European Federation of Pharmaceutical Industry Associations. Armin Kessler has a B Sc. in Physics and Chemistry from the University of Pretoria, a B. Sc. in Chemical Engineering from the University of Cape Town, a Juris Doctorate from Seton Hall University and an honorary doctorate in Business Administration from the University of Pretoria. He is a registered Patent Attorney at the USA Patent Office. He has served on the boards of Hoffmann-La Roche, Genentech, Syntex, PRA International and CroMedica. He currently serves on the Boards of Actelion, Gen-Probe, The Medicines Co. and Medgenisis.
| || ||Jon Stonehouse |
Jon Stonehouse, a pharmaceutical executive for more than 20 years, has strong commercialization, financial transaction, business development and management expertise. He joined BioCryst as President and CEO in January 2007. The transformation that has taken place since then has advanced BioCryst to a company with its first product revenue and approvals, pivotal clinical programs and a diverse clinical pipeline, as well as the financial flexibility to build an enduring, successful biopharmaceutical company. Before joining BioCryst, he served as Senior Vice President of Corporate Development at Merck KGaA with responsibility for global licensing and business development, corporate mergers and acquisitions, corporate strategic planning and alliance management. Among his accomplishments, he was responsible for leading the effort to develop a strategy for Merck that significantly changed the company, which culminated with the acquisition of Serono, S.A., the largest biotechnology company in Europe.
| || ||Henry Nordhoff |
Henery Nordhoff served as President and CEO of Gen-Probe Inc. for fifteen years until his retirement in May 2009, while he remains as the Chairman. Prior to joining Gen-Probe Inc., Mr. Nordhoff served as President and CEO of TargeTech, Inc., a gene therapy company focused on the treatment of inherited diseases, which was merged into the Immune Response Corporation in 1992. Previously, Nordhoff spent over 16 years at Pfizer Inc. where he held several senior positions in Brussels, Seoul, Tokyo and New York. Mr. Nordhoff is Vice Chairman of the Shipston Group, and leads the private equity firm’s healthcare investments in Asia. Mr. Nordhoff serves on the Board of Directors of the Prostate Cancer Foundation, MannKind Corporation and the San Diego Museum of Art. He is a member of the Advisory Committees of the UCSD School of Business Administration, the Jacobs School of Engineering at UCSD, the Rady School of Management at UCSD, and the International Advisory Board for Chugai Pharmaceutical Co., Ltd. of Tokyo. He is a member of the Founders Committee at the Preuss School and is a past Chairman of the California Healthcare Institute and the San Diego Regional Economic Corporation. Henry Nordhoff received his Bachelor of Arts degree in International Relations and Political Economy from Johns Hopkins University and earned a Master's degree in International Business and Finance from Columbia University.
| || ||Dr. Shan Lu |
Dr. Shan Lu is a tenured professor in the Department of Medicine at the University of Massachusetts Medical School (UMMS) and the director of Laboratory of Nucleic Acid Vaccines. He served as Chair for three US NIH panels to select candidate vaccines for national stockpiling against key biodefense targets. He is a recipient of numerous awards including the Howard Hughes Research Award for Physician Scientists and the Worcester Foundation Research Award. Dr. Lu is a world expert on novel vaccine development against a wide range of human pathogens, and a pioneer in DNA vaccines. He has over 120 publications in international scientific journals. He is a member of the Executive Board of the International Society for Vaccines (ISV) and one of its three executive officers. He was the co-chair for the 2nd - 4th Annual Global Vaccine and ISV Congress, and the chairman for 2010 International Conference on Gene-Based Vaccines. He serves either as associated editors or members of the editorial board for several international research journals including Vaccine, and PLoS One. He also holds adjunct professorship at multiple Chinese higher education and research institutions, and serves as adjunct director for the China-US Vaccine Center in Nanjing, China. He is an Executive Board member of China AIDS Vaccine Initiative (CAVI). Dr. Lu received his MD from Nanjing Medical University, China, PhD from the University of Massachusetts Medical School and Master of Health Administration (MHA) from Clark University. Dr. Lu is and associate director of Medicine Residency Program at UMMS.